Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 4,99 € (+1060,47 %). La mediana es de 4,99 € (+1060,47 %).
| Comprar |
4 |
| Mantener |
3 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Cresco Labs strengthens presence in Pennsylvania with purchase of PharmaCann for $50 million
Cresco Labs has acquired PharmaCann Penn for $50 million, gaining nine operational medical marijuana dispensaries in Pennsylvania. The payment was made in cash and via a seller note on a debt- and cash-free basis with a normalized target working capital level. Cresco expects the transaction to boost revenue, margins and cash flow and now operates in the state as both a retail and wholesale operator, running dispensaries under the Sunnyside brand and maintaining cultivation and wholesale activities. » Más en de.investing.com
Cresco Labs beats Q2 expectations, but stock remains under pressure
Cresco Labs reported Q2 2026 revenue of $173.34 million and adjusted EPS of -$0.01, with both metrics topping analyst expectations. Adjusted EBITDA rose to $40 million (23% margin) and adjusted gross profit was $89 million (52% margin), while operating cash flow amounted to $15 million. The stock is trading near its 52-week low as investors weigh continued negative earnings, a only flat outlook for Q3 (around $173 million in revenue) and persistent pressures in the cannabis sector. Management sees growth potential in Pennsylvania, Ohio and Kentucky and a positive impact from possible federal reform, but warns of risks from competition, pricing pressure and regulatory uncertainty. » Más en de.investing.com
Cresco Labs: analysts expect smaller quarterly loss on declining revenue on May 8
Cresco Labs will report results for the quarter ended March 31, 2026, on May 8, 2026. Four analysts on average estimate a loss of -0.023 USD per share (prior year -0.060 CAD), and six analysts forecast revenue of about 148.9 million USD (prior year 237.8 million CAD). For the current fiscal year, median analyst expectations are a loss of -0.075 USD per share and revenue of about 620.8 million USD (prior year 916.4 million CAD). » Más en finanzen.net
Cresco Labs launches at-the-market stock program for around US$100 million
Cresco Labs has established an at-the-market (ATM) program to permit the sale of subordinate voting shares totaling up to approximately US$100 million. A distribution agreement has been entered with Haywood Securities; no shares have been issued yet. Net proceeds are intended primarily for general corporate purposes and potential acquisitions. Sales will occur on the Canadian Securities Exchange and are not registered for a U.S. public offering. » Más en de.investing.com
Cresco Labs sells California business as part of strategic realignment
Cresco Labs has announced the sale of its operations in California to strengthen its balance sheet and cash flow, and to focus on higher-margin core markets. CEO Charlie Bachtell cited structural challenges and price pressure in the California market as reasons for the withdrawal. Analysts see uncertain short-term growth prospects, while the company continues to distribute its premium brand FloraCal in the US. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 152,54 M | 8,55 % |
| Beneficio bruto | 70,17 M | 3,77 % |
| Beneficio neto | -10,98 M | 24,42 % |
| EBITDA | 9,14 M | 46,04 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 156,67 M € |
Número de acciones | 361,07 M |
Máximo/mínimo de 52 semanas | 2,09 € - 0,42 € |
| Dividendos | No |
Beta | 1,72 |
Ratio P/E | -1,67 |
Ratio PEG | 0,01 |
Ratio P/B | 0,51 |
Ratio P/S | 0,26 |
Perfil de la empresa
Cresco Labs Inc., junto con sus subsidiarias, cultiva, fabrica y vende productos de cannabis recreativo y medicinal en Estados Unidos. Ofrece cannabis en flores, vaporizadores de pluma, resinas vivas, plumas desechables y extractos bajo la marca Cresco; cartuchos para vaporizar, plumas vaporizadoras, flores, popcorn, shake, pre-rolls, shorties y concentrados bajo la marca High Supply; vaporizadores y gomitas bajo la marca Good News; vaporizadores y comestibles bajo la marca Wonder Wellness Co; y tinturas, cápsulas, bálsamos y aceites sublinguales bajo la marca Remedi, así como productos de cannabis bajo la marca Reserve. La empresa también ofrece flores de cannabis bajo la marca FloraCal; y confites de chocolate y toffee, gomitas con sabor a frutas, caramelos duros y taffy bajo la marca Mindy's Edibles, además de licenciar la marca Kiva, que produce comestibles infusionados con cannabis, incluidos confites de chocolate, gomitas, mentas y tartas. Adicionalmente, la empresa ofrece comestibles infusionados con cannabis bajo la marca Sunnyside. Al 27 de enero de 2022, era propietaria y operaba 48 dispensarios. La empresa fue constituida en 1990 y tiene su sede en Chicago, Illinois.
| Nombre | Cresco Labs |
| CEO | Charles Bachtell |
| Sede | Chicago,
il Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Productos farmacéuticos |
| Salida a bolsa | 03/12/2018 |
| Empleados | 2900 |
Deep Dive
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
Cnq | CL.CN |
Pnk | CRLBF |
Frankfurt | 6CQ.F |
Düsseldorf | 6CQ.DU |
München | 6CQ.MU |